Terns Pharmaceuticals, Inc. Share Price & Technical Analysis
TERN · $52.95 (-0.04%)
Healthcare / Biotechnology
$52.95
-0.04%
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid ho…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
0% return in May, -2% avg return in past 3 year May month.
35% return in 2026, 59% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 21% | 29% | 0% | 0% | – | – | – | – | – | – | – | 35% |
| 25 | -20% | -14% | -24% | 18% | -6% | 16% | 49% | 23% | 9% | 11% | 99% | 45% | 205% |
| 24 | -20% | 40% | -11% | -28% | 20% | 10% | 15% | -1% | 9% | -17% | -10% | -11% | -5% |
| 23 | -12% | 12% | 18% | 12% | -18% | -17% | -18% | -26% | -6% | 6% | -17% | 44% | -23% |
| 22 | -11% | -48% | -9% | -47% | 6% | 47% | -16% | 77% | 51% | 11% | 11% | 31% | 105% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.12B
P/E ratio
—
52W high
$53.19
52W low
$2.65
Volume
63,31,482
Beta
-0.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Terns Pharmaceuticals, Inc. share price today?
- Terns Pharmaceuticals, Inc. (TERN) last traded around $52.95 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TERN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TERN. Download the app for real-time alerts.
- How can I analyze Terns Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.